HOME >> MEDICINE >> NEWS
Trends in private Medicare+Choice plans provide warnings for Medicare debate

New York City, June 25, 2003--As Congress debates Medicare proposals that would shift more beneficiaries into private insurance plans, legislators may first want to examine the often tumultuous history of the six-year-old Medicare+Choice program, Medicare's managed care alternative to its traditional fee-for-service program. According to a new policy brief from The Commonwealth Fund, many Medicare+Choice enrollees have been faced with a limited choice of plans in their area and instability in provider participation compared with fee-for-service Medicare, as well as significantly increased out-of-pocket costs--especially for those with chronic and disabling illnesses--and a confusing, complicated benefit structure.

"Seniors may suddenly find that their physician is no longer a member of their plan or, if they have health problems, that their out-of-pocket costs have increased substantially," said Karen Davis, president of The Commonwealth Fund. "These are the realities of the health care marketplace, and we should be cautious about inflicting them on the elderly and disabled."

The analysis, Lessons from Medicare+Choice for Medicare Reform, by Geraldine Dallek, an independent health policy consultant, and Brian Biles and Lauren Hersch Nicholas of George Washington University, provides seven lessons for the current debate:

    Lesson #1: Private plans do not participate in many regions. Attracting private plans to some regions, particularly rural areas, has been difficult because of the small number of hospitals and physicians in these areas and their reluctance to contract with managed care plans. Only 13% of rural beneficiaries have an option of joining a Medicare+Choice plan.

    Lesson #2: Premiums and benefits vary greatly by geographic area. Wide variation in premiums, benefits, and cost-sharing will undermine the promise of Medicare to provide the same health care benefits to beneficiaries no matter where they live.
    '"/>



Contact: Mary Mahon
mm@cmwf.org
212-606-3853
Commonwealth Fund
25-Jun-2003


Page: 1 2 3 4

Related medicine news :

1. American Heart Association Comment: Contributions Of Trends In Survival And Coronary-Event Rates To Changes In Coronary Heart Disease Mortality
2. Statement from Claude Lenfant, M.D., NHLBI Director, on Trends in Hypertension
3. New Research Identifies Outcomes And Future Trends Based On Past Behaviors, Experience
4. $2.8 million public-private partnership to examine how surroundings can encourage active lifestyles
5. Department of Energy announces new agreement with USC, national labs and private company
6. Extra Medicare payments for private health plans to total $2.75 billion in 2004
7. Keep prescribing information private
8. Emory, GlaxoSmithKline, NIMH enter public-private partnership to develop new drugs for depression
9. Report shows high arsenic in some southeast NH private wells
10. New Dallas biotech firm the result of unique public-private partnership
11. Survey: Medicare gets higher marks from enrollees than private insurance

Post Your Comments:
(Date:6/19/2013)... 2013 Maui'd Forever , Hawaii's ... being an effective and cost effective way to provide ... partnered up with Tom Barefoot’s Tours providing an activity ... of Hawaii’s activities. , They have just released a ... the lowest prices on their Hawaii activities. , ...
(Date:6/19/2013)... June 19, 2013 According to Transparency ... Market Share, Trends, Analysis and Forecast, 2011 – 2017,” ... billion in the year 2011 and is expected to ... CAGR of 9.7% from 2011 to 2017. Flexible endoscopes ... contributing about USD 2,201 million for the year 2011. ...
(Date:6/19/2013)... neurologists treating stroke victims has been "time equals brain." That,s ... receive a drug that dissolves the stroke-causing blood clot can ... saved or lost. , But specific information has ... intravenous drug known as a tissue plasminogen activator, or ... the most common type of stroke. , Now, ...
(Date:6/19/2013)... Il. A Loyola University Chicago Niehoff School of ... to study whether Vitamin D can improve mood in ... also will examine whether vitamin D supplementation can reduce ... diabetes. The grant is from the National Institute of ... Principal investigator Sue M. Penckofer, PhD, RN and colleagues ...
(Date:6/19/2013)... June 19, 2013 AquaPrint Solutions in Thomson, ... & Grub with a newly-designed Harley Davidson motorcycle gas tank. ... AquaPrint Solutions with an idea of taking a split tank ... ages and transforming it into a work of art. ... & Grub several toilet seats that had been dipped in ...
Breaking Medicine News(10 mins):Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)...  Decision Resources, one of the world,s leading ... issues, finds that, for the treatment of rheumatoid ... rheumatologists cite a therapy,s induction of remission as ... prescribing decisions. Over 60 percent and 70 percent ... percentage of patients achieving remission at six months ...
(Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics ... from a human abuse liability (HAL) study for NKTR-181, ... of entry into the brain.  This slow rate of entry ... the abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and ...
Breaking Medicine Technology:Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
Cached News: